ICRF-196

CAT: 0804-HY-118590ASize: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-118590ASize:1 Each
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ICRF-196 is an racemic mixture of the (S, S) - and (R, R) -isomers of ICRF-193 (HY-118590) . ICRF-193 is a DNA Topoisomerase II inhibitor. ICRF-193 can inhibit DNA syntheses and induces apoptosis. ICRF-193 exhibits anti-cancer and anti-inflammation effects. ICRF-193 shows cardioprotective effect against anthracycline toxicity to cardiomyocytes. ICRF-193 can be used for the researches of cancer, infection, inflammation and cardiovascular disease, such as acute promyelocytic leukemia[1][2][3][4][5][6].
CAS Number
[21416-68-2]
UNSPSC
12352005
Target
Apoptosis; DNA/RNA Synthesis; Fungal; Topoisomerase
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/icrf-196.html
Solubility
10 mM in DMSO
Smiles
CC(N(C1)CC(NC1=O)=O)C(N(C2)CC(NC2=O)=O)C
Molecular Formula
C12H18N4O4
Molecular Weight
282.30
References & Citations
[1]Nakazawa N, et al. ICRF-193, an anticancer topoisomerase II inhibitor, induces arched telophase spindles that snap, leading to a ploidy increase in fission yeast. Genes Cells. 2016 Sep;21 (9) :978-93.|[2]Niitsu N, et al. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30 (11) :1273-82.|[3]Hossain MS, et al. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells. Genes Cells. 2002 Mar;7 (3) :285-94|[4]Brindle A, et al. The Bisdioxopiperazine ICRF-193 Attenuates LPS-induced IL-1β Secretion by Macrophages. Inflammation. 2024 Feb;47 (1) :84-98.|[5]Jirkovská A, et al. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J Med Chem. 2021 Apr 8;64 (7) :3997-4019.|[6]Tanimoto C, et al. ICRF-193 modifies etoposide-induced apoptosis in thymocytes. Acta Med Okayama. 1995 Dec;49 (6) :281-6.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Topo II

Related Products

CatalogName
HY-118590-01ICRF-193
HY-100201-01A-196
HY-118379NU/ICRF 500
HY-100201RA-196 (Standard)
HY-19468-01ERB-196
HY-W1128972CRBN ligand-196
HY-170999Antitumor agent-196
HY-163397Antibacterial agent 196
HY-158019Anticancer agent 196
HY-W854844BJP-2-196 (hydrochloride)

Alternative Products

CatalogName
MF-0144383-01ICRF-196
BML-GR332-0005ICRF-193
MBS3845110-01A-196

Popular Products